Protagenic Therapeutics Stock Forecast - Simple Exponential Smoothing
| PTIX Stock | USD 0.58 0.15 34.88% |
The Simple Exponential Smoothing forecasted value of Protagenic Therapeutics on the next trading day is expected to be 0.58 with a mean absolute deviation of 0.1 and the sum of the absolute errors of 5.96. Protagenic Stock Forecast is based on your current time horizon.
At this time, the RSI of Protagenic Therapeutics' share price is approaching 31 indicating that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Protagenic Therapeutics, making its price go up or down. Momentum 31
Sell Stretched
Oversold | Overbought |
Wall Street Target Price 4 |
Using Protagenic Therapeutics hype-based prediction, you can estimate the value of Protagenic Therapeutics from the perspective of Protagenic Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The Simple Exponential Smoothing forecasted value of Protagenic Therapeutics on the next trading day is expected to be 0.58 with a mean absolute deviation of 0.1 and the sum of the absolute errors of 5.96. Protagenic Therapeutics after-hype prediction price | USD 0.58 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Protagenic | Build AI portfolio with Protagenic Stock |
Protagenic Therapeutics Additional Predictive Modules
Most predictive techniques to examine Protagenic price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Protagenic using various technical indicators. When you analyze Protagenic charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Protagenic Therapeutics Simple Exponential Smoothing Price Forecast For the 24th of January
Given 90 days horizon, the Simple Exponential Smoothing forecasted value of Protagenic Therapeutics on the next trading day is expected to be 0.58 with a mean absolute deviation of 0.1, mean absolute percentage error of 0.02, and the sum of the absolute errors of 5.96.Please note that although there have been many attempts to predict Protagenic Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Protagenic Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Protagenic Therapeutics Stock Forecast Pattern
| Backtest Protagenic Therapeutics | Protagenic Therapeutics Price Prediction | Buy or Sell Advice |
Protagenic Therapeutics Forecasted Value
In the context of forecasting Protagenic Therapeutics' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Protagenic Therapeutics' downside and upside margins for the forecasting period are 0.01 and 10.95, respectively. We have considered Protagenic Therapeutics' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of Protagenic Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Protagenic Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 114.0427 |
| Bias | Arithmetic mean of the errors | 0.0407 |
| MAD | Mean absolute deviation | 0.0977 |
| MAPE | Mean absolute percentage error | 0.0797 |
| SAE | Sum of the absolute errors | 5.96 |
Predictive Modules for Protagenic Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Protagenic Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Protagenic Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Protagenic Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Protagenic Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Protagenic Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Protagenic Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Protagenic Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Protagenic Therapeutics' historical news coverage. Protagenic Therapeutics' after-hype downside and upside margins for the prediction period are 0.03 and 10.86, respectively. We have considered Protagenic Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Protagenic Therapeutics is out of control at this time. Analysis and calculation of next after-hype price of Protagenic Therapeutics is based on 3 months time horizon.
Protagenic Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Protagenic Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Protagenic Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Protagenic Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
2.12 | 10.37 | 0.13 | 0.54 | 4 Events / Month | 6 Events / Month | In about 4 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
0.58 | 0.58 | 0.00 |
|
Protagenic Therapeutics Hype Timeline
Protagenic Therapeutics is at this time traded for 0.58. The entity has historical hype elasticity of -0.13, and average elasticity to hype of competition of -0.54. Protagenic is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is at this time at -2.12%. %. The volatility of related hype on Protagenic Therapeutics is about 4082.68%, with the expected price after the next announcement by competition of 0.04. The company has price-to-book ratio of 1.61. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Protagenic Therapeutics recorded a loss per share of 13.13. The entity last dividend was issued on the 27th of July 2016. The firm had 1:14 split on the 5th of May 2025. Given the investment horizon of 90 days the next forecasted press release will be in about 4 days. Check out Historical Fundamental Analysis of Protagenic Therapeutics to cross-verify your projections.Protagenic Therapeutics Related Hype Analysis
Having access to credible news sources related to Protagenic Therapeutics' direct competition is more important than ever and may enhance your ability to predict Protagenic Therapeutics' future price movements. Getting to know how Protagenic Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Protagenic Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| SLRX | Salarius Pharmaceuticals | (0.02) | 8 per month | 0.00 | (0.17) | 16.00 | (16.92) | 66.01 | |
| LIPO | Lipella Pharmaceuticals Common | 0.00 | 0 per month | 0.00 | (0.16) | 17.07 | (16.00) | 40.48 | |
| ARTL | Artelo Biosciences | (0.11) | 8 per month | 0.00 | (0.13) | 7.86 | (11.25) | 43.34 | |
| INDP | Indaptus Therapeutics | (0.19) | 10 per month | 0.00 | (0.02) | 13.58 | (12.56) | 51.64 | |
| SLXN | Biomotion Sciences Ordinary | 0.41 | 6 per month | 0.00 | (0.11) | 15.09 | (8.19) | 37.24 | |
| REVB | Revelation Biosciences | (0.64) | 5 per month | 0.00 | (0.16) | 5.56 | (8.33) | 20.39 | |
| CARM | Carisma Therapeutics | (0.64) | 2 per month | 9.24 | 0.08 | 22.92 | (14.06) | 62.59 | |
| SPRC | Scisparc | (0.12) | 7 per month | 0.00 | (0.33) | 5.00 | (12.20) | 30.69 | |
| GTBP | GT Biopharma | (0.64) | 2 per month | 6.87 | 0.03 | 10.84 | (10.45) | 51.03 | |
| PBM | Psyence Biomedical Ltd | (0.59) | 7 per month | 0.00 | (0.23) | 8.10 | (13.79) | 96.66 |
Other Forecasting Options for Protagenic Therapeutics
For every potential investor in Protagenic, whether a beginner or expert, Protagenic Therapeutics' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Protagenic Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Protagenic. Basic forecasting techniques help filter out the noise by identifying Protagenic Therapeutics' price trends.Protagenic Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Protagenic Therapeutics stock to make a market-neutral strategy. Peer analysis of Protagenic Therapeutics could also be used in its relative valuation, which is a method of valuing Protagenic Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Protagenic Therapeutics Market Strength Events
Market strength indicators help investors to evaluate how Protagenic Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Protagenic Therapeutics shares will generate the highest return on investment. By undertsting and applying Protagenic Therapeutics stock market strength indicators, traders can identify Protagenic Therapeutics entry and exit signals to maximize returns.
Protagenic Therapeutics Risk Indicators
The analysis of Protagenic Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Protagenic Therapeutics' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting protagenic stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 6.56 | |||
| Standard Deviation | 9.91 | |||
| Variance | 98.17 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Protagenic Therapeutics
The number of cover stories for Protagenic Therapeutics depends on current market conditions and Protagenic Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Protagenic Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Protagenic Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Protagenic Therapeutics Short Properties
Protagenic Therapeutics' future price predictability will typically decrease when Protagenic Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Protagenic Therapeutics often depends not only on the future outlook of the potential Protagenic Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Protagenic Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 4.9 M | |
| Cash And Short Term Investments | 1.8 M |
Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.